DENELSKY STEPHEN J 4

What Happened
Stephen J. Denelsky, a director of Harvard Bioscience, purchased 10,000 shares of the company's common stock in an open-market transaction on March 17, 2026 at $4.87 per share, a total purchase value of $48,700. This was a straight purchase (transaction code P), not an option exercise or award.

Key Details

• Transaction date and price: 2026-03-17, 10,000 shares @ $4.87 each (total $48,700).
• Shares owned after transaction: 21,000 beneficially owned (10,000 purchased + 11,000 restricted stock units).
• Notable footnotes: (1) The 11,000 RSUs fully vest on September 5, 2026. (2) A 10-for-1 reverse stock split on March 13, 2026 reduced previously reported 110,000 RSUs to 11,000; numbers in the filing reflect this split.
• Filing timeliness: Report filed 2026-03-18 for a 2026-03-17 transaction (timely filing).

Context
This is a direct open-market purchase by a company director, which increases his immediate stake; the RSUs are future ownership that vest later (Sept 5, 2026). Purchases are often considered more informative than routine sales, but the filing itself does not state the buyer’s motivation.